Tapinarof Cream 1% for Extensive Plaque Psoriasis: A Maximal Use Trial on Safety, Tolerability, and Pharmacokinetics.
John E JettMichael McLaughlinMark S LeeLawrence Charles ParishJanet DuBoisTooraj Joseph RaoofGlenn TaboltTimothy WilsonMatthew C SomervilleWayne DellaMaestraStephen C PiscitelliPublished in: American journal of clinical dermatology (2021)
Tapinarof cream 1% QD was well tolerated, with limited systemic exposure and significant efficacy at 4 weeks in patients with extensive plaque psoriasis. ClinicalTrials.gov Identifier NCT04042103.